India's GlaxoSmithKline Pharmaceuticals reported a higher adjusted third-quarter profit on Friday, led by sustained demand for its respiratory drugs and antibiotic Augmentin.

India's Glenmark Pharmaceuticals reported third-quarter profit below estimates on Friday due to bleak U.S. demand for its long-term illness drugs.

Vishal Manchanda highlights the potential challenges the pharmaceutical sector may face in FY27 due to reliance on key drugs ...

Results: Glenmark Pharmaceuticals posted a net profit of ₹348 crore in Q3 FY25, reversing a ₹351 crore loss YoY. Revenue ...

Thus far in the calendar year 2025, the Nifty Pharma index has slipped 11 per cent, as against 3.7 per cent fall in Nifty 50.

Trump announced reciprocal tariffs that could take effect against US trading partners, including India, as soon as April. The ...

Elara sees the ongoing weakness as an opportunity to buy into the pharma space, as it expects robust earnings growth ahead at ...

Aside from reciprocal tariffs, US President Trump has teased imposing tariffs on several import heavy sectors, including ...

The Nifty Pharma Index has taken a hit, dropping nearly 2% in Friday’s trade. Over the last five days, the index has declined by approximately 4.3%, and on a year-to-date basis, it has fallen by ...

India’s rapid digitalization and youthful population position it for long-term economic expansion, with its internet economy ...

Robert F Kennedy Jr takes charge of US HHS, USFDA, impacting Indian pharma exports, with focus on transparency and efficiency ...

GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024.